LUCIUS 卢修斯 阿西米尼 Asciminib白血病

阿西米尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Asciminib

老挝国家食药监局批准上市
老挝国家药检所检测认证

白血病

Composmows

3 ZAmg Asciminib

60 Tablets

HCL equivalent to Asciminib 40ma
LuciAsc is a kinase inhibitor indicated for the
trestment of adult patients with:
- Philadelohia chromosome-positive chronic
mveloid leukemia (Ph CML) in chrome phase

LuciAsc®

(cr). previously treated with two or more tyrosind
kinase innioitors (TKIs)
Pa- CML in CP Philadelphia chromosome-
nositive chronic mveloid leukemia (Ph+ CML) in
chronic phase (CP) with the T3151 mutation.

Asciminib Tablets

Dosage and Use:

FDA批准

kccommended Dosage in Ph+ CML in CP: 80 mg
orally once daily or 40 mg twice daily.

40mg

Recommendei
kecommended Dosagein Ph+ CML in CP with
the 13151 Mutation: 200 mg orally twice daily.
Avoid food for at least 2 hours before and I hour
after taking LuciAsc. Tablet should be swallowcd
whole & rot chewed or crushed.

Swallow tablets whole.Do not break,

Storage: in a dry place and store at 20C to 25℃.

crush,or chew the tablets.

Acep medicine out of the reach of Children.
Do not administered LuciAsc in Preenanc
Lactation patient treatment.
PLEASE SEE PACKAGEINSER
Manufactured and Marketed by

权威认证

LUCIUS

Thongmang village, Xaythaay distric

www.lucius

warning : To be sold ov retail on nrescn
Ma kegistered oncoloeist

LUCIUS

PHARMACEUTICALS

口碑质量

适应症:

1、既往使用过两种或多种酪氨酸激酶抑制剂(TKI)治疗,处于慢性期
(CP)的费城染色体阳性慢性粒细胞白血病 Ph+CML)的成年患者;
2、具有T3151突变的,处于慢性期(CP)的费城染色体阳性慢性粒细胞

白血病 Ph+CML)的成年患者。

推荐剂量:

1、CP中Ph+CML的推荐剂量:每日口服一次,每次80mg;或每日口服
两次,每次40mg;
2、T3151突变CP中Ph+CML的推荐剂量:每日口服两次,每次200mg;
3、空腹服用(餐前1小时或者餐后2小时服用);4、整片吞服,不要压碎或
咀嚼药片。